It’s time for oligonucleotide therapeutics to step into the light. With an increase in therapies in preclinical and clinical stages, many therapeutic developers find that they need to scale up quickly to meet demand.
Considering manufacturability and scale-up during small-scale method development will help deliver process efficiency and scalability, ensuring smooth technology transfer and saving time and materials. In this presentation, we’ll discuss strategies to future-proof your manufacturing for vaccines, therapeutics, and more.
Webinar Learning Objectives:
- An overview of the current clinical landscape for oligo therapeutics
- Key considerations for starting in-house oligonucleotide synthesis
- Considerations for clinical scale-up
